<DOC>
	<DOCNO>NCT00397904</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab may also stop growth tumor cell block enzyme need growth . Drugs use chemotherapy , cisplatin irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together cisplatin irinotecan may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together cisplatin irinotecan work treat patient metastatic esophageal cancer , gastroesophageal junction cancer , gastric cancer respond previous irinotecan cisplatin .</brief_summary>
	<brief_title>Cetuximab , Cisplatin , Irinotecan Treating Patients With Metastatic Esophageal Cancer , Gastroesophageal Junction Cancer , Gastric Cancer That Did Not Respond Previous Irinotecan Cisplatin</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient irinotecan hydrochloride- cisplatin-refractory metastatic esophageal , gastroesophageal junction , gastric cancer treat cetuximab , cisplatin , irinotecan hydrochloride . Secondary - Determine median survival patient treat regimen . - Determine tolerability regimen patient . - Determine adverse event profile patient treat regimen . - Assess epidermal growth factor receptor expression tumor tissue patient treat regimen . OUTLINE : This open-label , nonrandomized study . Patients receive cetuximab IV 60-120 minute day 1 , 8 , 15 cisplatin IV 30 minute irinotecan hydrochloride IV 30-90 minute day 1 8 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Patients undergo tumor biopsy baseline evaluate epidermal growth factor receptor immunohistochemistry . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Adenocarcinoma squamous cell carcinoma esophagus Adenocarcinoma gastroesophageal junction Adenocarcinoma stomach Metastatic disease Measurable disease diagnostic CT scan MRI Failed prior treatment cisplatin irinotecan hydrochloride , define follow : Radiographic progression within 12 weeks* last dose prior cisplatin irinotecan hydrochloride , administer either adjuvant neoadjuvant therapy , OR therapy metastatic disease NOTE : *Prior irinotecan hydrochloride cisplatin must administer within past 12 week ; chemotherapy regimen may administer time disease progression prior irinotecan hydrochloride/cisplatin study entry Pathologic tissue available immunohistochemistry ( IHC ) stain epidermal growth factor receptor ( EGFR ) Positive negative EGFR IHC allow PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % Life expectancy &gt; 3 month WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL Bilirubin normal AST ALT &lt; 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Creatinine ≤ 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior severe infusion reaction monoclonal antibody No history allergic reaction compound similar chemical biologic composition irinotecan hydrochloride , cisplatin , study agent No prior intolerance irinotecan hydrochloride cisplatin despite prior dose attenuation No uncontrolled illness include , limited , follow : Ongoing active infection require parenteral antibiotic Symptomatic congestive heart failure Unstable angina pectoris Uncontrolled hypertension Clinically significant cardiac arrhythmia Myocardial infarction within past 6 month HIV infection Psychiatric illness social situation would preclude study compliance No history Gilbert 's disease No medical condition reason would preclude study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics More 3 week since prior chemotherapy radiotherapy recover No 2 prior treatment regimens metastatic disease No prior therapy specifically directly target epidermal growth factor receptor pathway No prior anticancer murine chimeric monoclonal antibody therapy Prior humanize monoclonal antibody therapy allow No concurrent antiseizure medication know affect metabolism irinotecan hydrochloride , include phenytoin phenobarbital No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>